The VA has chosen ten sites for the first approved psychedelic therapies but expects treating even 1,000 veterans in year one to be a challenge. Also this week: DEA comments closed on scheduling five tryptamines, including the compound behind a postpartum depression drug, and a DEA judge declined to reopen the cannabis rescheduling hearing.
The post Weekly Psychedelic Policy Briefing: Oct. 27, 2026 appeared first on Psychedelics Today.
